<DOC>
	<DOCNO>NCT01308619</DOCNO>
	<brief_summary>The objective study determine clinical effect doxycycline 40 mg ( 30 mg immediate release 10 mg delay release bead ) capsule ( Oracea® ) compare placebo skin adult papulopustular rosacea identify correlation , , rosacea-related inflammatory marker .</brief_summary>
	<brief_title>Evaluation Rosacea-related Inflammatory Biochemical Markers Adult Skin When Treated With Oracea® v Placebo</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Subject male female age 18 70 year inclusive Subject papulopustular rosacea ( 5 40 papule pustule ) Subject active dermatological condition face may interfere conduct study Subject use proton pump inhibitor treatment gastroesophageal reflux within 30 day prior baseline visit study Subject use spironolactone within 30 day prior baseline visit study Subject require chronic treatment ( &gt; 14 day ) sulfa drug , erythromycin , cephalosporins quinolones within 30 day prior baseline visit study Subject use tetracycline antibiotic within 30 day prior baseline visit study Subject use penicillin antibiotic within 30 day prior baseline visit study Subject use topical oral dapsone Subject change hormonal therapy within 3 month initiation therapy study Subject use systemic immunosuppressant ( e.g . corticosteroid , cyclosporine , imuran , biologics , mycophenolate mofetil ) within 30 day prior baseline visit . For subject receive treatment biologics , treatment must discontinue within 90 day prior baseline Subject use systemic therapy direct improve rosacea , include antibiotic , within 30 day prior baseline visit Subject use systemic retinoids within 6 month baseline visit Subject take niacin dosage 500 mg per day Subject use topical rosacea therapy include topical antibiotic , topical retinoids , topical sodium sulfacetamide preparation , topical benzoyl peroxide , topical vasoconstricting agent ( e.g. , oxymetazoline ) topical calcineurin inhibitor ( e.g . tacrolimus , pimecrolimus ) within 30 day prior baseline visit Subject treat another investigational drug device within 30 day baseline visit . For subject receive experimental biologic treatment , treatment must discontinue within five half life baseline visit . Subject know allergy component study product , and/or know hypersensitivity tetracycline Subject use clinically significant concomitant drug ( e.g. , use long term nonsteroidal antiinflammatory agent unless use PRN basis le 7 day per month ) Subject use vasodilator adrenergic block agent within 6 week baseline visit ( except subject stable dose great 3 month ) Subject laser light therapy face within 3 month baseline visit Subject active ocular rosacea and/or blepharitis/meibomianitis require systemic treatment ophthalmologist Subject rhinophymatous rosacea Subject history noncompliance treatment regimen Subject risk term precaution , warning , contraindication ( see package insert ) Subject previously fail improvement rosacea appropriate use systemic tetracycline family antibiotic Subjects recent history alcohol and/or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>